270 related articles for article (PubMed ID: 32390331)
1. Metronomic chemotherapy of cyclophosphamide plus methotrexate for advanced breast cancer: Real-world data analyses and experience of one center.
Lu Q; Lee K; Xu F; Xia W; Zheng Q; Hong R; Jiang K; Zhai Q; Li Y; Shi Y; Yuan Z; Wang S
Cancer Commun (Lond); 2020 May; 40(5):222-233. PubMed ID: 32390331
[TBL] [Abstract][Full Text] [Related]
2. Oral metronomic cyclophosphamide and methotrexate plus fulvestrant in advanced breast cancer patients: a mono-institutional case-cohort report.
Aurilio G; Munzone E; Botteri E; Sciandivasci A; Adamoli L; Minchella I; Esposito A; Cullurà D; Curigliano G; Colleoni M; Goldhirsch A; Nolè F
Breast J; 2012 Sep; 18(5):470-4. PubMed ID: 22827581
[TBL] [Abstract][Full Text] [Related]
3. Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer.
Orlando L; Cardillo A; Ghisini R; Rocca A; Balduzzi A; Torrisi R; Peruzzotti G; Goldhirsch A; Pietri E; Colleoni M
BMC Cancer; 2006 Sep; 6():225. PubMed ID: 16978400
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Toxicity of Metronomic Chemotherapy in Metastatic Breast Cancer: Egyptian Experience.
Hussein MM; Gaafar RM; Abdel-Warith AM; Ahmed WA; Allahloubi NMA; Salem SE; Abdel-Salam IM
Clin Breast Cancer; 2017 Dec; 17(8):618-628. PubMed ID: 28625341
[TBL] [Abstract][Full Text] [Related]
5. Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group.
Wildiers H; Tryfonidis K; Dal Lago L; Vuylsteke P; Curigliano G; Waters S; Brouwers B; Altintas S; Touati N; Cardoso F; Brain E
Lancet Oncol; 2018 Mar; 19(3):323-336. PubMed ID: 29433963
[TBL] [Abstract][Full Text] [Related]
6. An all-oral combination of metronomic cyclophosphamide plus capecitabine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: a phase II study.
Wang Z; Lu J; Leaw S; Hong X; Wang J; Shao Z; Hu X
Cancer Chemother Pharmacol; 2012 Feb; 69(2):515-22. PubMed ID: 21874317
[TBL] [Abstract][Full Text] [Related]
7. Metronomic oral combination chemotherapy with capecitabine and cyclophosphamide: a phase II study in patients with HER2-negative metastatic breast cancer.
Yoshimoto M; Takao S; Hirata M; Okamoto Y; Yamashita S; Kawaguchi Y; Takami M; Furusawa H; Morita S; Abe C; Sakamoto J
Cancer Chemother Pharmacol; 2012 Aug; 70(2):331-8. PubMed ID: 22526409
[TBL] [Abstract][Full Text] [Related]
8. SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial.
Rochlitz C; Bigler M; von Moos R; Bernhard J; Matter-Walstra K; Wicki A; Zaman K; Anchisi S; Küng M; Na KJ; Bärtschi D; Borner M; Rordorf T; Rauch D; Müller A; Ruhstaller T; Vetter M; Trojan A; Hasler-Strub U; Cathomas R; Winterhalder R;
BMC Cancer; 2016 Oct; 16(1):780. PubMed ID: 27724870
[TBL] [Abstract][Full Text] [Related]
9. Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methotrexate, and daily prednisone as therapy for metastatic breast cancer using vascular endothelial growth factor and soluble vascular endothelial growth factor receptor levels as markers of response.
Wong NS; Buckman RA; Clemons M; Verma S; Dent S; Trudeau ME; Roche K; Ebos J; Kerbel R; Deboer GE; Sutherland DJ; Emmenegger U; Slingerland J; Gardner S; Pritchard KI
J Clin Oncol; 2010 Feb; 28(5):723-30. PubMed ID: 20026801
[TBL] [Abstract][Full Text] [Related]
10. Prolonged clinical benefit with metronomic chemotherapy in patients with metastatic breast cancer.
Orlando L; Cardillo A; Rocca A; Balduzzi A; Ghisini R; Peruzzotti G; Goldhirsch A; D'Alessandro C; Cinieri S; Preda L; Colleoni M
Anticancer Drugs; 2006 Sep; 17(8):961-7. PubMed ID: 16940806
[TBL] [Abstract][Full Text] [Related]
11. Metronomic oral chemotherapy with cyclophosphamide plus capecitabine combined with trastuzumab (HEX) as first line therapy of HER-2 positive advanced breast cancer: A phase II trial of the Gruppo Oncologico Italia Meridionale (GOIM).
Orlando L; Lorusso V; Giotta F; Di Maio M; Schiavone P; Fedele P; Quaranta A; Caliolo C; Ciccarese M; Cinefra M; Romito S; Pisconti S; Prete SD; Aieta M; Rizzi D; Maiello E; Colucci G; Cinieri S
Breast; 2020 Oct; 53():18-22. PubMed ID: 32540553
[TBL] [Abstract][Full Text] [Related]
12. Oral metronomic cyclophosphamide with and without methotrexate as palliative treatment for patients with metastatic breast carcinoma.
Gebbia V; Boussen H; Valerio MR
Anticancer Res; 2012 Feb; 32(2):529-36. PubMed ID: 22287742
[TBL] [Abstract][Full Text] [Related]
13. Phase II randomized trial comparing metronomic anthracycline-containing chemotherapy versus standard schedule in untreated HER2 negative advanced breast cancer: activity and quality of life results of the GOIM 21003 trial.
Orlando L; Maiello E; Orditura M; Diana A; Antoniol G; Morritti MG; Aieta M; Ciccarese M; Pisconti S; Bordonaro R; Russo A; Febbraro A; Schiavone P; Quaranta A; Caliolo C; Loparco D; Cinefra M; Colucci G; Cinieri S;
Breast; 2024 Jun; 75():103725. PubMed ID: 38615483
[TBL] [Abstract][Full Text] [Related]
14. Exploratory predictive and prognostic factors in advanced breast cancer treated with metronomic chemotherapy.
Miscoria M; Tonetto F; Deroma L; Machin P; Di Loreto C; Driol P; Minisini AM; Russo S; Andreetta C; Mansutti M; Damante G; Fasola G; Puglisi F
Anticancer Drugs; 2012 Mar; 23(3):326-34. PubMed ID: 22129512
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of metronomic chemotherapy as salvage therapy for patients with metastatic breast cancer.
Salem DA; Gado NM; Abdelaziz NN; Essa AE; Abdelhafeez ZM; Kamel TH
J Egypt Natl Canc Inst; 2008 Jun; 20(2):134-40. PubMed ID: 20029469
[TBL] [Abstract][Full Text] [Related]
16. A randomized phase II study of metronomic cyclophosphamide and methotrexate (CM) with or without bevacizumab in patients with advanced breast cancer.
Mayer EL; Tayob N; Ren S; Savoie JJ; Spigel DR; Burris HA; Ryan PD; Harris LN; Winer EP; Burstein HJ
Breast Cancer Res Treat; 2024 Feb; 204(1):123-132. PubMed ID: 38019444
[TBL] [Abstract][Full Text] [Related]
17. Metronomic chemotherapy combined with bevacizumab and erlotinib in patients with metastatic HER2-negative breast cancer: clinical and biological activity.
Montagna E; Cancello G; Bagnardi V; Pastrello D; Dellapasqua S; Perri G; Viale G; Veronesi P; Luini A; Intra M; Calleri A; Rampinelli C; Goldhirsch A; Bertolini F; Colleoni M
Clin Breast Cancer; 2012 Jun; 12(3):207-14. PubMed ID: 22520733
[TBL] [Abstract][Full Text] [Related]
18. Low-dose metronomic chemotherapy as an efficient treatment option in metastatic breast cancer-results of an exploratory case-control study.
Krajnak S; Schnatz C; Almstedt K; Brenner W; Haertner F; Heimes AS; Lebrecht A; Makris GM; Schwab R; Hasenburg A; Schmidt M; Battista MJ
Breast Cancer Res Treat; 2020 Jul; 182(2):389-399. PubMed ID: 32495001
[TBL] [Abstract][Full Text] [Related]
19. Metronomic oral cyclosphosphamide as third-line systemic treatment or beyond in patients with inoperable locoregionally advanced recurrent or metastatic nasopharyngeal carcinoma.
Lee VHF; Kwong DLW; Lam KO; Lai YC; Li Y; Tong CC; Ho PPY; Chan WL; Wong LS; Leung DKC; Chan SY; Chan FT; Leung TW; Lee AWM
Medicine (Baltimore); 2017 Apr; 96(15):e6518. PubMed ID: 28403082
[TBL] [Abstract][Full Text] [Related]
20. Metronomic Chemotherapy vs Best Supportive Care in Progressive Pediatric Solid Malignant Tumors: A Randomized Clinical Trial.
Pramanik R; Agarwala S; Gupta YK; Thulkar S; Vishnubhatla S; Batra A; Dhawan D; Bakhshi S
JAMA Oncol; 2017 Sep; 3(9):1222-1227. PubMed ID: 28384657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
